Demographics, baseline characteristics, median follow-up and percentage of tumor relapse of the patients at the time of the analyses
| Molecular classification (surrogate), n (%) | Total | POLE-mutated | MMRd/MSI | CNL | CNH |
| 47 | 7 (14.9) | 15 (31.9) | 17 (36.2) | 8 (17) | |
| Age, mean±SD, years | 70.36±10.28 (52–91) | 66.6±13.2 (55–91) | 69.2±10.1 (52–90) | 71.9±10.3 (55–89) | 72.6±8.2 (63–90) |
| Endometrioid | 37 (78.7) | 5 (71.4) | 14 (93.3) | 16 (94.1) | 2 (25) |
| Serous | 3 (6.4) | – | – | – | 3 (37.5) |
| Undifferentiated | 1 (2.1) | 1 (14.3) | – | – | – |
| Mixed | 2 (4.3) | 1 (14.3) | 1 (6.7) | – | – |
| Carcinosarcoma | 4 (8.5) | – | – | 1 (5.9) | 3 (37.5) |
| G1 | 15 (31.9) | 1 (14.3) | 4 (26.7) | 10 (58.9) | – |
| G2 | 6 (12.8) | – | 3 (20) | 3 (17.6) | – |
| G3 | 26 (55.3) | 6 (85.7) | 8 (53.3) | 4 (23.5) | 8 (100) |
| FIGO I–II | 35 (74.5) | 6 (85.7) | 10 (66.7) | 16 (94.1) | 3 (37.5) |
| FIGO III | 9 (19.1) | 1 (14.3) | 5 (33.3) | 1 (5.9) | 2 (25) |
| FIGO IV | 3 (6.4) | – | – | – | 3 (37.5) |
| Relapse, n (%) | 18 (38.3) | – | 6 (40) | 6 (35.3) | 6 (75) |
| Median follow-up times (years) | 3.8 | 3.9 | 3.7 | 3.1 |
CNH, copy-number high; CNL, copy-number low; FIGO, International Federation of Gynecology and Obstetrics staging system; MMRd/MSI, mismatch repair deficient or microsatellite instable; POLE, polymerase-ε.